FOLIC.ACID

Click to edit text. What do visitors to your website need to know about you and your business?

 No direct studies turned up linking folic acid specifically to osteogenesis imperfecta. Let me check a couple more specific angles before concluding.

Examined mechanistic pathways linking folate metabolism to bone collagen integrity

Short answer: no, there isn't a dedicated body of research specifically studying folic acid's effect on osteogenesis imperfecta (OI). I didn't find any OI-specific folic acid trials, cohort studies, or mouse-model work in the search results.

What does exist, and what's likely adjacent to what you're thinking of:

General bone health / folate literature (not OI-specific)
There's a reasonably well-established literature on folate, vitamin B12, and homocysteine in relation to bone mineral density and fracture risk in the general population — mostly postmenopausal women. A longitudinal study by Cagnacci et al. (2008) found folate was associated with bone mineral density changes independent of its homocysteine-lowering effect, suggesting folic acid's role in bone health may go beyond just lowering homocysteine levels. But this is general-population osteoporosis research, not OI. Naturalhealthresearch

The mechanistic link that might be relevant to your work
The more plausible connection to OI isn't folic acid directly — it's homocysteine and collagen cross-linking. Elevated homocysteine (as seen in classical homocystinuria, a different genetic disorder) is known to interfere with lysyl oxidase-mediated collagen cross-linking, weakening the collagen matrix. Since OI is fundamentally a type I collagen cross linking/structure disorder (whether via COL1A1/COL1A2 mutations or cross linking enzymes like PLOD2/FKBP10), there's a theoretical mechanistic overlap worth flagging: normal bone collagen depends on hydroxylation of cross linking lysine residues that enable stable inter-molecular cross-links in the extracellular matrix, and homocysteine metabolism intersects with this same cross linking machinery. That's speculative extrapolation on my part though — I'm not aware of anyone having actually tested folate/homocysteine status or MTHFR polymorphisms as a modifier in OI patients specifically. nih

If you want, I can dig further into:

1. Whether any OI natural history studies included folate/B12/homocysteine as covariates (sometimes buried in supplementary data on nutritional status)

2. MTHFR polymorphisms studies as OI severity modifiers specifically

3. Recent (2025-2026) preprints/registries that might not be indexed yet

Want me to chase any of those threads down?

I would love any and all information that you might be able to find on the folate/b12/homocysteine idea, I know that OI doesn't have close connection with mineralizatuion, so that rules out the initial thought, but the co variants are a good lead to follow. Thanks'

Marshaled research on folate-B12-homocysteine pathways and documented findings

This is a genuinely unexplored angle — I found nothing directly testing folate/B12/homocysteine in OI patients specifically, but the mechanistic case is stronger than the mineralization-focused hypothesis, and there's decent literature to build on.

The core mechanism (well-established, not OI-specific)

Homocysteine directly interferes with collagen cross linking — not through mineralization, but through the lysyl oxidase pathway. This is the load-bearing citation: elevated homocysteine has been shown in-vitro to impair collagen cross linking, and separately affects both osteoclast and osteoblast activity, leading to bone fragility. This tracks with what's known from classical homocystinuria (CBS deficiency), where connective tissue fragility and skeletal abnormalities are a recognized feature, and the mechanism is attributed to homocysteine disrupting lysyl oxidase-mediated cross linking of collagen.

That's a clean fit for OI, since OI is — as you noted — fundamentally a collagen structure/cross linking disorder rather than a mineralization disorder. Homocysteine acting on the same cross linking chemistry that's already compromised by the underlying COL1A1/COL1A2 (or PLOD2/FKBP10 cross linking-enzyme) mutation is a plausible "second hit" hypothesis — worse cross linking on top of already-abnormal cross linking

What's known in general (non-OI) bone populations

• A study of postmenopausal Chinese-Singaporean women found folate and B12 status associated with bone mineral density and hip strength, and reiterated that high homocysteine impairs collagen cross linking and affects both osteoclast and osteoblast activity, leading to poor bone health and fragility fractures.

• Interestingly, that same paper notes B-complex supplementation lowered homocysteine in older adults but didn't improve bone turnover biomarkers — so the relationship isn't simply "supplement folate → better bones." The literature is inconsistent on BMD/fracture outcomes overall.

• Genetic evidence (Mendelian randomization) in osteoarthritis found homocysteine has adverse causal effects while folate and B12 were protective — a different joint/cartilage pathology, but reinforces homocysteine as a plausible causal (not just correlated) factor in connective tissue outcomes generally.

What's missing — the actual gap

I could not find:

• Any study measuring homocysteine, folate, or B12 status specifically in OI patients or cohorts

• Any MTHFR C677T/A1298C genotyping study using OI severity as an outcome (I checked — MTHFR-as-severity-modifier studies exist for Rett syndrome and Legg-Calvé-Perthes disease, but nothing for OI)

• Any OI natural history study that included homocysteine/folate/B12 as a co-variate, even incidentally

So this looks like a genuinely open question rather than a well-trodden one. Given that OI natural history registries already collect fracture frequency, bone density, and genotype data on large cohorts, adding a homocysteine/folate panel would be a low-cost, high-plausibility add — the kind of thing that could plausibly justify a letter to a natural history study PI or a retrospective chart review if any center's biobank already has serum stored.

Want me to try to find whether any of the major OI natural history studies (Linked Clinical Research Centers, BBD Consortium, etc.) bank serum that could retroactively support this, or look at whether MTHFR variant frequency data exists in any OI genomics cohort as a byproduct of exome sequencing?

yes please do thanks

Verified absence of data and prepared comprehensive response

Here's what I found on both fronts.

Bio-bank lead — this is real and promising

The Brittle Bone Disorders Consortium (BBDC), the 14-center NIH-funded network that runs the "Longitudinal Study of osteogenesis Imperfecta" (the largest OI research project to date, successor to the original 5-center Linked Clinical Research Centers), explicitly collects blood samples specifically for research at regular intervals, alongside DNA testing and clinical/radio-logical data, as part of its observational cohort design. Baylor College of Medicine is the lead site, PI is Dr. Brendan Lee, with Dr. Reid Sutton as Administrative Director.

That's the biobank you'd want to approach. A few practical notes:

• Whether stored serum/plasma specifically permits retrospective folate/B12/homocysteine assay (vs. having been used up or stored in a format unsuitable for that panel) isn't stated anywhere public — that's a question for the BBDC directly, likely through a data/sample access request process common to Rare Diseases Clinical Research Network (RDCRN) consortia.

• Homocysteine assay from stored frozen serum is fairly robust; folate is more finicky (light-sensitive, degrades) but often still workable depending on storage conditions.

• The RDCRN generally has a formal ancillary study / sample request mechanism for outside investigators — worth locating that process page if you want to pursue this as a real proposal rather than just a research question.

Exome/genomic cohort lead — dead end, confirmed

I checked several OI whole-exome sequencing studies (Russian cohort, Pakistani/consanguineous families, rare-gene diagnostic series) to see if any reported MTHFR variants as incidental or secondary findings. None do — these are all targeted diagnostic analyses focused solely on the causative OI gene (COL1A1/COL1A2/WNT1/FKBP10/SERPINF1/etc.), and none report secondary findings panels that would surface something like MTHFR C677T. So there's no existing dataset to mine for this — it would have to be prospectively collected.

Net assessment

This is a genuine, unpublished research gap with a plausible mechanism and an identifiable pathway to pursue it (BBDC sample/data access), not just a dead-end curiosity. If you want, I can draft a one-page research question / rationale memo laying out the hypothesis and citations in a form suitable for approaching a BBDC investigator or including in a grant/pilot-study pitch.

Well, that was exciitng wasnt it?

Hello...you awake> move your mouse....

OK, so, bottom line is that thus far there has been no published research or thought movement in this area at all.

Additionally, IF the Folic Acid in the wheat/flour is making an OI patient encounter fewer fractures it may not necessarily be the folic acid itself, insttead the Folic Acid may be acting as a "carrier" that helps the body move the elements that IT needs for bne health into the proper places where the body can reach them and use them.

Obviously this is  a huge research hole that we need to have someone dig into. I have a medical school near me, and Im sure you have one within 100 miles of you.

Additonally every Chiropractor I have ever met has an interest in Holistic/Alternative medicone, this fits right in their wheel house.

More  importantly, as I was finishing up this page I had an interview with a Dr. that I have great respect for, while she has no direct experience with OI she can add anecdotally that she has seen major changes in children with Autism. I know Autism and OI seem miles apart and thats true, however I think we all recognize that at the moment Autism is very present in the countries conversation, so hopefully we can piggy back onto that conversation!